[Note: This PDQ summary contains content that is also included in the PDQ Childhood Medulloblastoma and PDQ Childhood Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma summaries. In the very near future, the PDQ Childhood Medulloblastoma and PDQ Childhood Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma summaries will be removed from the National Cancer Institute’s (NCI) cancer.gov website.]

The National Cancer Institute provides the PDQ pediatric cancer treatment information summaries as a public service to increase the availability of evidence-based cancer information to health professionals, patients, and the public. The PDQ Childhood brain tumor treatment summaries are organized primarily according to the 2000 World Health Organization for the classification of nervous system tumors.[1]

In recent decades, dramatic improvements in survival have been achieved for children and adolescents with cancer. Childhood and adolescent cancer survivors require close follow-up because cancer therapy side effects may persist or develop months or years after treatment. Refer to the PDQ summary on Late Effects of Treatment for Childhood Cancer for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.

Primary brain tumors are a diverse group of diseases that together constitute the most common solid tumor of childhood. Brain tumors are classified according to histology, but tumor location and extent of spread are important factors that affect treatment and prognosis. Immunohistochemical analysis, cytogenetic and molecular genetic findings, and measures of mitotic activity are increasingly used in tumor diagnosis and classification. Refer to the PDQ summary on Childhood Brain and Spinal Cord Tumors for information about the general classification of childhood brain and spinal cord tumors.

References

1. Kleihues P, Cavenee WK, eds.: Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer, 2000. 
   
   

Back to Top

< Previous Section  |  Next Section >